Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Stage/Subtype:  multiple myeloma
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-7 of 7 for your search:
Start Over
Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC038C, NCI-2009-01194, Mod06-005263-65, MAYO-MC038C, MAYO-06-005263, NCT00450814
Laboratory-Treated Therapeutic Autologous Lymphocytes in Treating Patients With Advanced Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: UPCC 01411, NCI-2011-00960, NCT01352286
Vaccine Therapy and Therapeutic Autologous Lymphocytes in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: UPCC 07409, NCI-2011-02940, NCT01426828
Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes in Treating Patients with High-Risk Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: J1343, NCI-2013-01767, NA_00084466, NA_00084466 / CIR00005616, NCT01858558
Vaccine Therapy in Treating Patients with Stage I-III Multiple Myeloma Undergoing Stem Cell Transplant
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-009, NCI-2013-02282, NCT01995708
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 247913, NCI-2014-02621, NCT02334865
Vaccine Therapy in Treating Patients with Multiple Myeloma Who Have Undergone Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-288, NCI-2013-00802, NCT01827137
Start Over